Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

MYCO-005

From Wikipedia, the free encyclopedia
Psychedelic drug
Pharmaceutical compound
MYCO-005
Clinical data
Other namesMYCO005
Drug classSerotonin5-HT2A receptoragonist;Serotonergic psychedelic;Hallucinogen[1][2][3]

MYCO-005 is aserotonin5-HT2A receptoragonist andpsychedelichallucinogen which is under development for the treatment ofdepressive disorders andanxiety disorders.[1][2][4][3][5]

It is anaza-indoleanalogue ofpsilocin and hence atryptamine relative.[1][3][6] However, whereas psilocin and other tryptamines show highaffinity for andpotent activation of not only the serotonin 5-HT2A receptor but also the serotonin5-HT2B receptor, MYCO-005 does not bind to this receptor.[1][3] Activation of the serotonin 5-HT2B receptor is known to induce the development ofcardiac valvulopathy and has been a concern with regard to chronicmicrodosing of psychedelics.[7][8] Since MYCO-005 does not activate the serotonin 5-HT2B receptor, it is anticipated to beheart-safe and to be safer for use in the contexts of both macro- and microdosing than other psychedelics.[1][3][5]

As of February 2024, MYCO-005 is in the research stage of development for depressive disorders and anxiety disorders.[1] It is being developed byMydecine.[1][2] The exactchemical structure of MYCO-005 does not yet seem to have been disclosed.[1] However, thecompound waspatented in 2023 and the specified patent specifically describesaza-substituted psilocin analogues.[5][9]

See also

[edit]

References

[edit]
  1. ^abcdefgh"Research programme: second generation psilocin analogs".AdisInsight. 13 February 2024. Retrieved1 November 2024.A family of psilocin analogs (MYCO 005) with heart-safe microdose enabling properties is being developed by Mydecine Innovations Group for the treatment of [...]
  2. ^abc"Delving into the Latest Updates on MYCO-005 with Synapse".Synapse. 1 November 2024. Retrieved1 November 2024.
  3. ^abcde"Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules".BioSpace. 16 February 2022. Retrieved1 November 2024.
  4. ^"MYCO-005 Drug Profile".Ozmosi. 26 October 2023. Retrieved1 November 2024.
  5. ^abcMydecine Innovations Group (18 December 2023)."Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound".Yahoo Finance. Retrieved1 November 2024.
  6. ^"Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds".BioSpace. 7 February 2024. Retrieved27 March 2025.
  7. ^Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R (September 2023). "The risk of chronic psychedelic and MDMA microdosing for valvular heart disease".J Psychopharmacol.37 (9):876–890.doi:10.1177/02698811231190865.PMID 37572027.
  8. ^Rouaud A, Calder AE, Hasler G (March 2024)."Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins".J Psychopharmacol.38 (3):217–224.doi:10.1177/02698811231225609.PMC 10944580.PMID 38214279.
  9. ^"Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same".Google Patents. 1 May 2023. Retrieved1 November 2024.
Tryptamines
No ring subs.
4-Hydroxytryptamines
5-Hydroxytryptamines
5-Methoxytryptamines
Other ring subs.
α-Alkyltryptamines
Others
Cyclized
Bioisosteres
Phenethylamines
Scalines
2C-x
3C-x
DOx
4C-x
Ψ-PEA
MDxx
FLY
25x-NB (NBOMes)
Others
Cyclized
Lysergamides
  • Bioisosteres:JRT
Others
Natural sources
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=MYCO-005&oldid=1284988101"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp